$GILD Company News Seven health stocks with buy signals

New Post Public Reply Private Reply Replies (0) Message Board

Dec 19, 2014 at 10:48 AM

$GILD Company News

Seven health stocks with buy signals 10:21 a.m. Dec. 11, 2014 - The Trading Deck
Newscast: Oil called the tune on Wall St. 4:21 p.m. Dec. 10, 2014 - MarketWatch
Cypress, Spansion shares rally on merger plan 5:36 p.m. Dec. 1, 2014 - MarketWatch
Mylan to manufacture, distribute Gilead Sciences HIV drug 7:49 a.m. Dec. 1, 2014 - Angela Chen
10 stocks that may revisit their highs as the year ends 10:30 a.m. Nov. 24, 2014 - Philip van Doorn
Are consumers getting gouged on health care? 9:35 a.m. Nov. 22, 2014 - Russ Britt
Gilead Sciences shares slide 1.7% 9:35 a.m. Nov. 19, 2014 - Sue Chang
The double-edged sword of growth-stock speculation 2:29 p.m. Nov. 14, 2014 - The Trading Deck
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Merck, Dendreon miss out on health-care rally 12:39 p.m. Nov. 10, 2014 - Russ Britt
Gilead Sciences rises 2% to top S&P 500 gainers 9:31 a.m. Nov. 10, 2014 - Sue Chang
Visa shares rise after hours on earnings beat 6:50 p.m. Oct. 29, 2014 - Sue Chang
Warren Buffett best wear his trunks as Fed preps to end (pause) the printing 8:34 a.m. Oct. 29, 2014 - Shawn Langlois
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Updates, advisories and surprises 5:01 p.m. Oct. 28, 2014 - MarketWatch
Sales of Gilead's pricey hepatitis C drug slow 4:26 p.m. Oct. 28, 2014 - MarketWatch.com
Gilead Sciences' stock pulls back from record high close after earnings miss 4:14 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead's stock drops 3.6% in after-hours trade after Q3 results 4:09 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead revises 2014 product sales outlook to $22 bln-$23 bln from $21 bln-$23 bln 4:08 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 Sovaldi sales $2.8 bln vs. $3.48 bln in Q2 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore

The 2015 Calendar Of NASH Trial Catalysts IV: GENFIT And Gilead 8:28 a.m. Today - Seeking Alpha
Update: News On Gilead From The California Technology Assessment Forum 5:45 a.m. Today - Seeking Alpha
Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug 10:50 p.m. Dec. 18, 2014 - The Wall Street Journal Interactive Edition
Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally 8:10 p.m. Dec. 18, 2014 - TheStreet.com
Alexion's Rare Disease Model Analyzed 3:23 p.m. Dec. 18, 2014 - Seeking Alpha
Biogen Idec Poised To Continue Its Stellar Run 12:46 p.m. Dec. 18, 2014 - Seeking Alpha
Is it Time to Sell Gilead Sciences? 10:27 a.m. Dec. 18, 2014 - GuruFocus.com
Chimerix and ContraVir team up in antiviral development 10:23 a.m. Dec. 18, 2014 - Seeking Alpha
2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses 9:35 a.m. Dec. 18, 2014 - TheStreet.com
Ho Ho Harvoni: Gilead Sciences Is A Gift That Should Be Under Every Investor's Tree. 7:36 a.m. Dec. 18, 2014 - Seeking Alpha
AbbVie Pins Hopes on Hepatitis C Treatment 7:52 p.m. Dec. 17, 2014 - The Wall Street Journal Interactive Edition
A 'Wisdom Of Experts' Portfolio 12:15 p.m. Dec. 17, 2014 - Seeking Alpha
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know 9:20 a.m. Dec. 17, 2014 - TheStreet.com
Gilead Sciences Stands Alone 7:44 a.m. Dec. 17, 2014 - Seeking Alpha
Examining Gilead Sciences' Future Pipeline 7:37 a.m. Dec. 17, 2014 - Seeking Alpha
Meet 5 Big Tech Stocks Expected To See Profits Surge 8:03 p.m. Dec. 16, 2014 - Investors Business Daily
Assessing Gilead's Reality-Perception Gap 11:52 a.m. Dec. 16, 2014 - Seeking Alpha
4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog 11:26 a.m. Dec. 16, 2014 - Zacks.com
How To Beat The Market - My Best Large-Cap Stock Portfolio: Gilead Sciences 10:04 a.m. Dec. 16, 2014 - Seeking Alpha
2015 Healthcare Sector Predictions 6:50 a.m. Dec. 16, 2014 - Seeking Alpha

Reveal Earnings Forecast for Apple, Halliburton, American Realty Capital Properties, Gilead Sciences, Zynga, and Bank of America 8:45 a.m. Dec. 16, 2014 - PR Newswire - PRF
Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutics 8:30 a.m. Dec. 15, 2014 - BusinessWire - BZX
Critical Alerts For Abercrombie & Fitch, Whole Foods Market, Gilead Sciences, JC Penney and Activision Blizzard Released By InvestorsObserver 9:31 a.m. Dec. 10, 2014 - PR Newswire - PRF
Class Action Lawsuit Challenges the Exorbitant Pricing of Gilead's Hepatitis-C Drug Sovaldi 6:39 p.m. Dec. 9, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases February Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:43 p.m. Dec. 9, 2014 - PR Newswire - PRF
Biogen Idec and Gilead Sciences Join the National Pharmaceutical Council 9:15 a.m. Dec. 9, 2014 - PR Newswire - PRF
Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 10:00 a.m. Dec. 8, 2014 - BusinessWire - BZX
Reveal Earnings Forecast for Gilead Sciences, Apple, Transocean, Halliburton, Ctrip, and Sirius XM 8:45 a.m. Dec. 8, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for Gilead Sciences, Kinder Morgan, JD.Com, Sirius XM, Apple, and Plug Power 8:45 a.m. Dec. 4, 2014 - PR Newswire - PRF
Earnings Forecast Reports for Apple, Alibaba, Kinder Morgan, Gilead Sciences, Plug Power, and Yahoo 8:45 a.m. Dec. 2, 2014 - PR Newswire - PRF
Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries 7:00 a.m. Dec. 1, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for Apple, Alibaba, Hewlett-Packard, Gilead Sciences, Petrobras, and BlackBerry 8:45 a.m. Nov. 26, 2014 - PR Newswire - PRF
Critical Alerts For SouFun, Petroleo Brasileiro, Gilead Sciences, Transocean and iRobot Released By InvestorsObserver 9:31 a.m. Nov. 24, 2014 - PR Newswire - PRF
Earnings Forecast Research for Kinder Morgan, Petrobras, Freeport-McMoRan, Keurig Green Mountain, Gilead Sciences, and Alibaba 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Resources, Gilead Sciences, Apple, and Plug Power 8:45 a.m. Nov. 20, 2014 - PR Newswire - PRF
Knight Sells Priority Review Voucher to Gilead 5:11 p.m. Nov. 19, 2014 - Marketwired
European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 10:07 a.m. Nov. 18, 2014 - BusinessWire - BZX
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba 8:45 a.m. Nov. 18, 2014 - PR Newswire - PRF
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com 8:45 a.m. Nov. 14, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...